C12N 2740/13032
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2740/13032 (Use of virus as therapeutic agent, other than vaccine) appears on 18 US grants and 15 published applications in this corpus.
Search patents in C12N- Granted patents
- 18
- Published applications
- 15
- Assignees
- 14
- Inventors
- 40
- Latest grant
- 14 Nov 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 4 | 0 |
| 1999 | 2 | 0 |
| 2000 | 2 | 0 |
| 2001 | 0 | 0 |
| 2002 | 2 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 1 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 2 |
| 2017 | 2 | 0 |
| 2018 | 0 | 2 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 2 | 2 |
| 2022 | 0 | 1 |
| 2023 | 2 | 0 |
| 2024 | 0 | 1 |
| 2025 | 0 | 1 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Retroviral and lentiviral vectors14 Nov 2023US 11,814,641 B2Autolus Limited
- Retroviral and lentiviral vectors28 Feb 2023US 11,591,613 B2Autolus Limited
- Retroviral vector with mini-promoter cassette20 Jul 2021US 11,065,311 B2Denovo Biopharma LLC
- Retroviral and lentiviral vectors23 Mar 2021US 10,954,530 B2Autolus Limited
- Compositions comprising gamma retrovirus vectors and methods of treating proliferative disorders6 Jun 2017US 9,669,049 B2Tocagen Inc.
- Stem cell based delivery of tumor-specific retroviral vectors21 May 2026US 2026/0139275 A1Abintus Bio, Inc.
- Retroviral and Lentiviral Vectors25 Dec 2025US 2025/0388929 A1Autolus Limited
- Retroviral And Lentiviral Vectors21 Mar 2024US 2024/0093232 A1Autolus Limited
- Methods of promoting long-term survival of patients with advanced chemotherapy-resistant malignancies16 Jun 2022US 2022/0184228 A1
- Enhanced cancer treatment and monitoring using recombinant vectors25 Nov 2021US 2021/0361691 A1Denovo Biopharma LLC
Most cited
By later US patents
- Recombinant retroviruses57US 5,716,613 AChiron Viagene, Inc. · 1998
- Recombinant retroviruses56US 5,716,826 AChiron Viagene, Inc. · 1998
- Recombinant retroviruses expressing a protein that converts a pro-drug into a cytotoxic agent43US 5,691,177 A1997
- Recombinant retroviruses42US 5,851,529 A1998
- Recombinant retroviruses16US 5,888,502 A1999